The estimated Net Worth of Megan Sniecinski is at least $2.52 Milión dollars as of 18 November 2019. Ms. Sniecinski owns over 45,000 units of Biocryst Pharmaceuticals stock worth over $347,850 and over the last 5 years she sold BCRX stock worth over $0. In addition, she makes $2,176,950 as Senior Vice President a Chief Business Officer at Biocryst Pharmaceuticals.
Megan has made over 1 trades of the Biocryst Pharmaceuticals stock since 2019, according to the Form 4 filled with the SEC. Most recently she bought 45,000 units of BCRX stock worth $65,250 on 18 November 2019.
The largest trade she's ever made was buying 45,000 units of Biocryst Pharmaceuticals stock on 18 November 2019 worth over $65,250. On average, Megan trades about 11,250 units every 0 days since 2019. As of 18 November 2019 she still owns at least 45,000 units of Biocryst Pharmaceuticals stock.
You can see the complete history of Ms. Sniecinski stock trades at the bottom of the page.
Megan Sniecinski serves as Senior Vice President, Chief Business Officer of the Company. She served as Senior Vice President of Business Operations and Program Management at PTC Therapeutics, Inc. (“PTC”), a global biopharmaceutical company, from 2017 to 2019, and as Vice President, Business Operations at PTC from 2014 to 2017. Prior to joining PTC, Ms. Sniecinski held various positions at Merck & Co., Inc., a global health care company, from 2002 to 2014, most recently as Chief of Staff to the President and Director of Business Development and Strategic Partnerships with Merck Vaccines. Ms. Sniecinski holds a B.S. in Chemical Engineering from the University of Virginia and an Executive M.B.A. from the Wharton School at the University of Pennsylvania.
As the Senior Vice President a Chief Business Officer of Biocryst Pharmaceuticals, the total compensation of Megan Sniecinski at Biocryst Pharmaceuticals is $2,176,950. There are 1 executives at Biocryst Pharmaceuticals getting paid more, with Jon Stonehouse having the highest compensation of $2,284,300.
Megan Sniecinski is 39, she's been the Senior Vice President a Chief Business Officer of Biocryst Pharmaceuticals since 2019. There are 22 older and no younger executives at Biocryst Pharmaceuticals. The oldest executive at Biocryst Pharmaceuticals Inc. is Robert Ingram, 77, who is the Independent Chairman of the Board.
Megan's mailing address filed with the SEC is 4505 EMPEROR BOULEVARD, SUITE 200, DURHAM, NC, 27703.
Over the last 24 years, insiders at Biocryst Pharmaceuticals have traded over $76,362,383 worth of Biocryst Pharmaceuticals stock and bought 4,042,003 units worth $20,848,654 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Brothers Life Sciences Capi... a Carl L Gordon. On average, Biocryst Pharmaceuticals executives and independent directors trade stock every 31 days with the average trade being worth of $542,329. The most recent stock trade was executed by Amy E Mc Kee on 24 June 2024, trading 8,600 units of BCRX stock currently worth $54,352.
biocryst pharmaceuticals, a biotechnology company, designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. founded in 1986, biocryst has more than 50 employees and is experiencing continued growth. the company’s headquarters are located in research triangle park, north carolina and its discovery center of excellence is in birmingham, alabama. with expertise in drug discovery, clinical development, regulatory affairs and product commercialization, we continue to advance our clinical programs and to generate new compounds from our own discovery engine. we are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. the commitment of biocryst remains unchanged. we continue to be passionate about developing and marketing novel therapeutics for patients with rare and serious diseases.
Biocryst Pharmaceuticals executives and other stock owners filed with the SEC include: